Minerva Capital Research Solutions

Morepen Laboratories

NSE: MOREPENLABBSE: 500288
₹ 90.75▼ 3.91 (−4.13%)17 Nov, 03:29 pm IST
Market cap
₹ 5,466 Cr.
P/E
29x
P/B
4.17x
52-week range
33.05 – 150.7
ROE
5%
ROCE
8%
Dividend yield
0.2%
Debt / equity
0.17
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 222 companies →

Morepen Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)29 against a typical 34: cheaper than most peers (1st = cheapest).93rd of 221
  • Sales growth+81.1% against a typical +17.5% from a year earlier.22nd of 200
  • Profit growth+117.1% against a typical +23.3% from a year earlier.26th of 163
  • Share price, 3 months+2.6% against a typical −0.1%.91st of 212
  • Size₹ 5,465.8 Cr. market value against a typical ₹ 485 Cr. (1st = largest).52nd of 206

Latest announcements

Exchange filings and their impact on the company.

  • 9 Nov 2026Press ReleaseLow impactPositivePrice +5% that day
    Morepen launched its first US prescription generic and filed its first US ANDA, a strategic step with small near-term sales.

    Morepen Laboratories launched its first US prescription generic, Desloratadine Tablets 5mg in 100 and 500 counts, through its US arm Morepen Bio Inc, building on years of API supply. It also filed its first US ANDA for Sitagliptin Phosphate Tablets in 25mg, 50mg and 100mg strengths, now under FDA review. The move extends Morepen from API and OTC into US finished-dose distribution, with more filings planned where its API strengths help.

    Filing
  • 27 Oct 2026Outcome of Board MeetingHigh impactVery positivePrice +4.9% that day
    Q2 revenue up 81% and profit up 118% with margins doubling and Rs 317 cr contingent liability removed.

    Morepen Laboratories reported very strong Q2 FY27 consolidated results with revenue of Rs 746.5 crore, up 81% from last year, and net profit of Rs 88.9 crore, up 118%. For the first half, revenue was Rs 1316.6 crore and net profit was Rs 145.3 crore, already above full FY26 profit. The company also disclosed that on 14 October 2026 the Himachal Pradesh High Court quashed a Rs 117.94 crore GST demand, removing a Rs 317.37 crore contingent liability.

    Filing
  • 14 Oct 2026General UpdatesHigh impactPositivePrice −2.1% on 15 Oct
    HP High Court quashed Rs 118 cr GST refund demand, removing a profit-sized liability overhang.

    Morepen Laboratories said the Himachal Pradesh High Court on 12 October 2026 quashed a Central GST show cause notice seeking recovery of Rs 117.94 crore towards excess GST refund plus interest and penalty. The order, received on 14 October 2026, decides the writ petition in the company's favour. This removes a large contingent liability equal to more than a year's profit and clears a major cash-flow overhang.

    Filing

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

Adequate safety

Rated A by Infomerics
A
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
InfomericsIVR AStable17 Nov 2026
Credit rating actions
RatingDetails
17 Nov 2026
▲ Upgrade1 notch
IVR A- → IVR AHighInfomerics₹ 225 Cr.
22 Aug 2025
New rating
IVR A-—Infomerics₹ 225 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
27 Oct 2026Financial ResultsTo consider and approve the financial results for the period ended September 30, 2026
4 Aug 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
26 May 2026Financial Results/Dividend/Other business mattersMOREPENLAB : 26-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 22, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 26, 2026, To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters
10 Feb 2026Financial Results/Other business mattersTo consider and approve the financial results for the period ended December 31, 2025 and other business matters
14 Nov 2025Financial ResultsTo consider and approve un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30th September 2025
6 Aug 2025Financial Results/Other business mattersTo consider and approve the financial results for the period ended Jun 30, 2025 and other business matters

Share price

1Y change +96.09%
0 of 3 filing days came with a big price move
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales445423455438453466425412484485570746
Expenses394375404394417424401381438460488623
Operating Profit5148524436422431462483123
OPM %11%11%11%10%8%9%6%7%10%5%14%16%
Other Income4435554304859
Interest211115444455
Depreciation81062516911106810
Profit before tax4442484635261646352375117
Tax %27%32%25%24%24%21%26%10%22%33%24%24%
Net Profit322936352720114128165689
EPS in Rs0.630.550.710.640.490.370.20.750.50.291.031.62

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
14%
5 Years
9%
3 Years
8%
TTM
30%
Compounded Profit Growth
10 Years
14%
5 Years
−8%
3 Years
18%
TTM
150%
Stock Price CAGR
10 Years
19%
5 Years
21%
3 Years
59%
TTM
—
Return on Equity
10 Years
12%
5 Years
10%
3 Years
9%
TTM
—

Shareholding

Latest: Sep 2026.

Promoters
35.66%
0 pts in a year
FIIs
3.43%
+1.81 pts in a year
DIIs
1.7%
+0.21 pts in a year
Government
0.01%
0 pts in a year
Public
59.19%
−2.03 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 29xEPS (12 months) ₹ 3.44Median P/E 31.5x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Morepen Laboratories₹ 90.75₹ 5,466 Cr.29x4.2x5%—
Sun Pharmaceutical Industries₹ 1,880.00₹ 4,51,064 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 11,442.00₹ 3,03,749 Cr.73x11.4x16.2%24.3%
Torrent Pharmaceuticals₹ 4,662.15₹ 1,77,327 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,391.80₹ 1,12,438 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,189.90₹ 1,18,693 Cr.21.2x4.2x19.7%18.5%

Management

Sushil Suri
Executive Chairman of the Board, Managing Director
Ajay Kumar Sharma
Chief Financial Officer
Vipul Kumar Srivastava
Compliance Officer, Company Secretary
Sanjay Suri
Managing Director

Prices are delayed and for information only. Nothing on this page is investment advice.